Integrating patient-specific clinical and biological factors towards individualizing utilization of proton and photon radiation therapy.

整合患者特定的临床和生物学因素,实现质子和光子放射治疗的个体化利用。

基本信息

  • 批准号:
    10270304
  • 负责人:
  • 金额:
    $ 294.04万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-21 至 2026-08-31
  • 项目状态:
    未结题

项目摘要

OVERALL - SUMMARY This is a joint application for a program project grant by Massachusetts General Hospital and MD Anderson Cancer Center. The progress we made in our most recent program projects (a P01 and a U19) has been criti- cal to the clinical, physical, and biological aspects of proton therapy and its significance as an important cancer treatment modality. The main achievements of the recently completed U19 (end date 8/31/20) were (1) the de- velopment and activation of definitive esophagus, liver and glioma randomized proton vs. photon therapy trials in cooperation with NRG, NCI and NCTN; (2) understanding and modeling the differences in response of nor- mal tissues to highly disparate proton and photon dose distribution patterns; (3) understanding the complexities of the biological effects of protons relative to photons; and (4) the development of advanced intensity modu- lated proton therapy incorporating physical uncertainties and the variable biological effectiveness of protons. Our research also revealed major gaps in the knowledge of the biological effects of protons, significant limita- tions of the current population-based models of normal tissue and tumor response to protons vs. photons, and uncertainty in the appropriateness of proton therapy in the face of heterogeneities in patient characteristics and treatment techniques in unselected groups of patients. On the bright side, our research also discovered the strong potential of proton therapy to reduce suppression of the immune system, which is commonly associated with photon therapy and has been shown to lead to adverse outcomes. The overall goals of the proposed P01 are (a) understanding relative clinical, biological and immunosuppressive effects of proton therapy vs. photon therapy; (b) enhancing outcomes based on the physical, biological and immunological properties of protons and photons; and (c) applying individualized (as opposed to population-based) approaches for the se- lection of the optimum radiation modality for each patient and to enhance the potential for outcomes with the use of radiation dose distributions tailored to the individual patient’s baseline and tumor characteristics. The achievement of these goals will be carried out in three projects. Project 1: Understanding Normal Tissue Tox- icity to Identify Patients Most Likely to Benefit from Proton vs. Photon Therapy; Project 2: Radiation-Induced Lymphopenia (RIL): Understanding, Predictive Modeling and Developing Photon and Proton-Based Mitigation Strategies; and Project 3: Investigating Enhanced Sensitivity of Tumors to Proton Beam Therapy: Mechanisms and Biomarkers. The projects are highly integrated in that decisions regarding treatment modality selection, treatment technique and optimization to maximally enhance the therapeutic ratio cannot be accomplished by any one project alone. Such decisions must consider and balance normal tissue complications, tumor re- sponse based on genotypic factors, and radiation-induced immunosuppression. The three projects will be sup- ported by an Administrative Core and three resource cores: Core 1: Data Management and Computational Support; Core 2: Translational Biospecimens and Imaging Biomarkers; and Core 3: Biostatistics.
Overall—概要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Theodore S Hong其他文献

Emerging evidence-based role for external-beam radiation therapy in hepatocellular carcinoma
外束放疗在肝细胞癌中新兴的基于证据的作用
  • DOI:
    10.1016/s2468-1253(24)00267-x
  • 发表时间:
    2025-04-01
  • 期刊:
  • 影响因子:
    38.600
  • 作者:
    Stephanie O Dudzinski;Neil B Newman;Jeff McIntyre;Reena Engineer;Nina N Sanford;Jennifer Y Wo;Jinsil Seong;Chandan Guha;Daniel T Chang;Theodore S Hong;Laura A Dawson;Eugene J Koay;Ethan B Ludmir
  • 通讯作者:
    Ethan B Ludmir

Theodore S Hong的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Theodore S Hong', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10270308
  • 财政年份:
    2021
  • 资助金额:
    $ 294.04万
  • 项目类别:
Integrating patient-specific clinical and biological factors towards individualizing utilization of proton and photon radiation therapy.
整合患者特定的临床和生物学因素,实现质子和光子放射治疗的个体化利用。
  • 批准号:
    10491819
  • 财政年份:
    2021
  • 资助金额:
    $ 294.04万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10491867
  • 财政年份:
    2021
  • 资助金额:
    $ 294.04万
  • 项目类别:
Improving the Clinical Effectiveness and Understanding of the Biophysical Basis
提高临床有效性和对生物物理基础的理解
  • 批准号:
    9334068
  • 财政年份:
    1997
  • 资助金额:
    $ 294.04万
  • 项目类别:

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 294.04万
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    $ 294.04万
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 294.04万
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    $ 294.04万
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    $ 294.04万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 294.04万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    $ 294.04万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 294.04万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    $ 294.04万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    $ 294.04万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了